期刊文献+

大剂量地塞米松联合rhTPO治疗初治重症原发免疫性血小板减少症疗效观察 被引量:2

Effect Observation of High-dose Dexamethasone and rh TPO on Initial Treatment Severe ITP
下载PDF
导出
摘要 目的观察大剂量地塞米松结合rh TPO治疗初治原发免疫性血小板减少症(ITP)的疗效。方法选取我院2014年1月~2016年7月收治的初治重症ITP患者40例,随机分为两组,对照组及观察组,各20例,两组患者均给予地塞米松,观察组在此基础上加用rh TPO。观察两组患者疗效及不良反应发生情况。结果观察组治疗总有效率(75%)高于对照组(30%),差异有统计学意义(P〈0.05);观察组不良反应总发生率(15%)低于对照组(20%),差异无统计学意义(P〉0.05)。结论rhT PO结合大剂量地塞米松治疗初治ITP临床疗效好,且患者治疗过程中不良反应发生情况少。 Objective To investigate the clinic effect of high-dose dexamethasone and rh TPO on initial treatment severe ITP. Methods 40 cases with ITP in our hospital from January 2014 to July 2016 were selected and divided into control group and observation group, 20 cases in each group. They were all given dexamethasone and observation group was added with rh TPO. Observe the effect and adverse reactions of the two groups. Results Total efficiency of observation group(75%) was higher than control group(30%), the difference was statistically significant(P〈0.05), adverse reaction rate of observation group(15%) was lower than control group(20%), the difference was not statistically significant(P〈0.05). Conclusion High-dose dexamethasone and rh TPO has significant effect on initial treatment severe ITP, adverse reactions is less during treatment.
作者 魏炜
出处 《中国继续医学教育》 2016年第33期202-204,共3页 China Continuing Medical Education
关键词 地塞米松 RHTPO ITP 治疗疗效 Dexamethasone rh TPO ITP Treatment effect
  • 相关文献

参考文献8

二级参考文献87

  • 1赵永强,王庆余,翟明,徐健,陈协群,刘文励,张梅,宋善俊,王健民,孟凡义,单渊东.重组人血小板生成素治疗慢性难治性特发性血小板减少性紫癜的多中心临床试验[J].中华内科杂志,2004,43(8):608-610. 被引量:102
  • 2Zhou B, Zhao H, Yang RC, et al. Multi-dysfunctional pathophysiology in ITP[J]. Crit Rev Oncol/Hematol, 2005, 54(2):107-116. 被引量:1
  • 3Zhou Z, Yang R. Rituximab treatment for chronic refractory idiopathic thrombocytopenic purpura[J]. Crit Rev Oncol Hematol, 2008, 65(1):21-31. 被引量:1
  • 4Wang T, Wang Z, Yang R. Thrombopoietic growth factors in the treatment of immune thrombocytopenic purpura[J]. Crit Rev Oncol Hematol, 2011,77(3):172-183. 被引量:1
  • 5Wang S, Yang R, Zou P, et al. A multicenter randomized controlled trial of recombinant human thrombopoietin treatment in patients with primary immune thrombocytopenia[J]. Int J Hematol, 2012, 96(2):222-228. 被引量:1
  • 6Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group[J]. Blood, 2009, 113(11):2386-2393. 被引量:1
  • 7Terrell DR, Beebe LA, Vesely SK, et al. The incidence of immune thrombocytopenic purpura in children and adults: a critical review of published reports[J]. Am J Hematol, 2010, 85(3):174-180. 被引量:1
  • 8D’Orazio JA, Neely J, Farhoudi N. ITP in children: pathophysiology and current treatment approaches[J]. J Pediatr Hematol Oncol, 2013, 35(1):1-13. 被引量:1
  • 9Zhao H, Li H, Zhang L, et al. Retrospective analysis of 472 Chinese children with chronic idiopathic thrombocytopenic purpura: a single center experience[J]. Haematologica, 2005, 90(6):860-861. 被引量:1
  • 10Wendling F, Maraskovsky E, Debili N, et al. cMpl ligand is a humoral regulator of megakaryocytopoiesis[J]. Nature, 1994, 369(6481):571-574. 被引量:1

共引文献130

同被引文献14

引证文献2

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部